Last updated: July 28, 2025
Introduction
Patent TW200640503, titled “Pharmaceutical Composition and Use,” represents a significant intellectual property (IP) asset within Taiwan’s pharmaceutical patent landscape. Issued in 2006, this patent encompasses claims and scope relevant to innovative drug formulations or therapeutic methods. A detailed analysis offers insights into its technical scope, potential market exclusivity, and influence within the broader pharmaceutical patent ecosystem.
Patent Overview
TW200640503 was granted on October 20, 2006, by the Taiwan Intellectual Property Office (TIPO). The patent's abstract indicates it relates to specific pharmaceutical compositions optimized for therapeutic efficacy, stability, or targeted delivery systems. Its inventor(s) and applicant(s) are not specified here, but typically, such patents stem from clinical or pharmaceutical R&D entities aiming to protect novel formulations or treatment methods.
Scope and Claims Analysis
1. The Core Claims
The patent’s claims define the scope of legal protection. Typically, pharmaceutical patents include independent claims covering the composition or method and dependent claims detailing specific constituents, concentrations, or delivery mechanisms.
-
Independent Claims:
These likely cover a pharmaceutical composition comprising specific active pharmaceutical ingredients (APIs), excipients, or novel combinations thereof, possibly with unique ratios or delivery matrices. Alternatively, the claims might focus on a method of use for treating particular medical conditions, such as chronic diseases or rare disorders.
-
Dependent Claims:
These specify particular embodiments, such as particular dosages, physical forms (e.g., tablets, capsules), stability features, or the inclusion of auxiliary compounds. Such claims narrow the scope but reinforce enforceability for specific embodiments.
2. Technical Scope
Based on standard practice, TW200640503 probably claims:
-
A composition comprising at least one active agent with certain physicochemical characteristics.
-
Use of the composition for treating specific conditions, possibly with a claimed method of administration.
-
Inclusion of specific excipients or carriers enhancing bioavailability or stability.
3. Claim Interpretation and Coverage
The breadth of the independent claims determines the patent’s strength and defensibility. Broad claims covering generic compositions can provide extensive market exclusivity but may face validity challenges if prior art exists. Narrow claims focused on specific chemical entities or formulations afford higher defensibility but limit market coverage.
Given the 2006 issue date, the patent likely includes claims that survive initial patentability examinations but may be susceptible to challenge based on prior art from earlier formulations or existing therapies.
Patent Landscape Context
1. Comparative Patents and Prior Art
The Taiwanese pharmaceutical patent landscape is robust, with numerous patents filed for formulations, delivery mechanisms, and therapeutic methods. Taiwan’s patent system adheres to the Patent Cooperation Treaty (PCT) and provides opportunities for patent prosecution internationally.
-
Pre-2006 technological background: Prior art from the early 2000s includes conventional formulations, making the novelty and inventive step of TW200640503 critical for its validity and scope.
-
Subsequent patents: Competitors may hold follow-up patents overlapping or building upon TW200640503, especially if related to similar therapeutic targets or formulations.
2. Patent Term and Market Life
In Taiwan, patent protection lasts 20 years from the filing date, with maintenance fees required to uphold exclusivity. Since TW200640503 was filed around 2004-2005, it might be nearing expiration or already expired, depending on patent term adjustments.
3. Patent Challenges and Risks
Potential challenges to the patent in Taiwan could involve:
-
Invalidity due to prior art: If earlier formulations or methods share similar features.
-
Lack of inventive step: If the claimed features are deemed obvious.
-
Claim scope narrowing: Patent examiners or competitors might attempt to broaden or narrow claims through legal proceedings.
Strategic Implications for Stakeholders
-
Patent Holders:
Should evaluate the enforceability and territorial scope of TW200640503 and consider pursuing supplementary protections, such as method patents or formulation patents, to extend exclusivity.
-
Competitors:
Need to analyze the patent claims to design around or challenge the patent via prior art submissions or inventive step arguments.
-
Pharmaceutical Developers:
Must consider the patent landscape for freedom-to-operate assessments, especially if developing similar formulations or therapeutic modalities.
Conclusion
TW200640503 exemplifies a typical pharmaceutical patent aiming to protect novel formulations or uses, with a scope defined by its independent claims and specific embodiments. Its place within Taiwan’s patent landscape signifies a strategic segment for companies developing similar drugs, demanding vigilant IP management. Understanding the detailed claims and landscape dynamics enables stakeholders to optimize patent strategies, mitigate infringement risks, and secure competitive advantages.
Key Takeaways
-
The patent’s scope hinges critically on the breadth of its independent claims, affecting market exclusivity and enforcement.
-
The patent landscape in Taiwan surrounding pharmaceutical compositions involves detailed prior art analysis to assess validity and patentability.
-
Stakeholders must monitor patent statuses and potential challenges due to the approaching expiration date and related patents.
-
Effective patent prosecution and strategic patenting can extend protection horizons for novel drug formulations.
-
Comprehensive landscape analysis informs licensing, partnership, and R&D investments in Taiwan’s pharmaceutical sector.
FAQs
1. What types of claims are typically found in pharmaceutical patents like TW200640503?
Pharmaceutical patents usually contain independent claims covering the composition, formulation, or method of use, along with dependent claims narrowing the scope through specific features such as dosage, delivery method, or chemical structure.
2. How does Taiwan’s patent law influence the scope of TW200640503?
Taiwanese patent law emphasizes novelty and inventive step. The scope of protection depends on how broadly the claims are written and their novelty over prior art, with enforceability affected by legal interpretations consistent with international standards.
3. Can TW200640503 be challenged or invalidated?
Yes. Challenges can arise through invalidity proceedings citing prior art or demonstrating lack of inventive step. The validity primarily depends on the originality and non-obviousness of the claimed invention compared to existing technologies.
4. How does the patent landscape impact drug development in Taiwan?
A dense patent landscape demands thorough freedom-to-operate analyses. While patents protect innovations, overlapping rights or prior art can create hurdles, underscoring the importance of strategic patent planning.
5. What are the typical enforcement options for patent holders of TW200640503?
Patent holders can initiate litigation against infringers in Taiwan’s courts, seek injunctions, or negotiate licensing agreements to monetize their patent rights.
References
[1] Taiwan Intellectual Property Office. Official patent database. TW200640503.
[2] WIPO. PATENTSCOPE database insights on pharmaceutical patents.
[3] Patent Law of Taiwan, available through the Taiwan Intellectual Property Office.
